Abstract THU0356 – Figure 2: Total collagen content

Abstract THU0356 – Figure 3: ADSC cell count measured by flow cytometry

Disclosure of Interests: None declared

THU0337

COMPARISON OF THE EFFICACY OF TWO RITUXIMAB REGIMENS IN THE PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE

Olgia Koneva, Lidia P. Ananyeva, Ludmila Garzanova, Oxana Desinova, Olga Ovsyannikova, Mayya Starovoytova. V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: Rituximab (RTM) is considered as a promising therapeutic agent for treatment of interstitial lung disease (ILD) in the patients with systemic sclerosis (SSc). However, the limited number of RTM-treated patients, heterogeneity of the studies in relation to main parameters, considerably different dose regimens, cumulative doses, and observation periods do not allow univocal conclusions on RTM efficacy or definitive recommendations on RTM use in the patients with SSc. The question whether to combine RTM with immunosuppressants (IS) or it is possible to use it as a single-agent therapy in the patients with SSc associated with ILD is still relevant.

Objectives: To compare the time courses of pulmonary function parameters and dermal fibrosis parameters during the use of RTM in combination with IS and as a single-agent therapy in the patients with SSc associated with ILD in the open-label prospective non-randomized study.

Methods: 90 patients with the confirmed SSc diagnosis and ILD evidence were enrolled into the study. All patients received low-dose and moderate-dose prednisolone regimens. Group A (n=45) received a total RTM dose 3.1±1.2 g in combination with IS (27/60% mycophenolate mofetyl, 16/35.6% cyclophosphamide, 2/4.4% methotrexate; the patient’s average age was 47±11.8 years, with female proportion 82%; SSc duration 4.6±3.5 years; diffused/localized forms 1.5/1). Group B (n=45) received RTM as a single therapy agent in a total dose 2.7±1 g (average age 45.0±15 years, female proportion 82%, SSc duration 6.7±5.6 years, diffused/localized forms 1.5/1). The age, gender proportion, SSc form, FVC and DLCO, and RTM cumulative doses were similar in the both groups. The follow-up period was 42 months. The time courses of FVC, DLCO, modified skin count (mRss, points), activity index (EScSG, points) were assessed in the study.

Results: In Groups A and B during the therapy significant decrease in mRss (p<0.00034 and 0.000002 respectively) and EScSG (p=0.00011 and 0.000000 respectively), FVC increase (p<0.00017 and 0.00001, respectively), and stabilization of the DLCO were observed. The treatment groups did not differ significantly in the median FVC increment, clinically meaningful FVC and DLCO increments of decrements, and EScSG and mRss time courses.

Parameters

<table>
<thead>
<tr>
<th>Group</th>
<th>EScSG 1</th>
<th>EScSG 2</th>
<th>mRss 1</th>
<th>mRss 2</th>
<th>FVC 1 ± SD</th>
<th>FVC 2 ± SD</th>
<th>Δ FVC%</th>
<th>Δ DLCO%</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>3.2±1.9</td>
<td>1.6±1.3</td>
<td>1.1±0.9</td>
<td>7.2±5.6</td>
<td>76±20.3*</td>
<td>82.7±22.5*</td>
<td>5.7</td>
<td>1.3</td>
</tr>
<tr>
<td>B</td>
<td>3.1±1.7</td>
<td>1.2±0.9</td>
<td>11.5±3.9</td>
<td>5.6±4.2</td>
<td>77.8±19.7*</td>
<td>86.8±19.7*</td>
<td>8.3</td>
<td>2.1</td>
</tr>
</tbody>
</table>

Notes: in Parameters column 1 = before treatment, 2 = after treatment; M ± SD = mean value and standard deviation; * = significant difference between the values measured before and after the treatment

Conclusion: RTM administration both in combination with IS and as a single-agent therapy in the patients with SSc associated with ILD effectively alleviated skin induration and EScSG, improved or stabilized the pulmonary function parameters. The absence of statistically significant difference in the time course of evaluated parameters between the groups substantiate potential RTM use as a single-agent therapy that, this is most important for the patients with poor tolerability or contraindications to IS administration.

Disclosure of Interests: None declared

THU0338

SIMVASTATIN-CONJUGATED NANOPARTICLE ENHANCES THE THERAPEUTIC EFFECT OF ADIPOSE-DERIVED STEM CELLS ON INTERSTITIAL LUNG DISEASE

Takuya Kojani, Takayasu Suzuki, Shogo Matsuoka, Il Masaaki, Tohru Takeuchi, Shigeki Arawaka. Osaka Medical College, Takatsuki, Japan

Background: Interstitial lung disease (ILD) associated with connective tissue disease is a life-threatening pathological condition that causes respiratory failure when it progresses. Lung inflammation is treated with corticosteroids and immunosuppressants, and pulmonary fibrosis is treated with anti-fibrosis agents such as pirfenidone and nintedanib. However, many cases are treatment-resistant and the outcome is poor. Moreover, adverse effects such as infections resulting from immunosuppressive therapy are problematic. The development of new treatments is thus required.

Methods: 90 patients with confirmed ILD and ILD evidence based on HRCT findings were enrolled into the study. All patients received low-dose and moderate-dose prednisolone regimens. Group A (n=45) received a total RTM dose 3.1±1.2 g in combination with IS (27/60% mycophenolate mofetyl, 16/35.6% cyclophosphamide, 2/4.4% methotrexate; the patient’s average age was 47±11.8 years, with female proportion 82%; SSc duration 4.6±3.5 years; diffused/localized forms 1.5/1). Group B (n=45) received RTM as a single therapy agent in a total dose 2.7±1 g (average age 45.0±15 years, female proportion 82%, SSc duration 6.7±5.6 years, diffused/localized forms 1.5/1). The age, gender proportion, SSc form, FVC and DLCO, and RTM cumulative doses were similar in the both groups. The follow-up period was 42 months. The time courses of FVC, DLCO, modified skin count (mRss, points), activity index (EScSG, points) were assessed in the study.

Results: In Groups A and B during the therapy significant decrease in mRss (p<0.00034 and 0.000002 respectively) and EScSG (p=0.00011 and 0.000000 respectively), FVC increase (p<0.00017 and 0.00001, respectively), and stabilization of the DLCO were observed. The treatment groups did not differ significantly in the median FVC increment, clinically meaningful FVC and DLCO increments of decrements, and EScSG and mRss time courses.

Parameters

<table>
<thead>
<tr>
<th>Group</th>
<th>EScSG 1</th>
<th>EScSG 2</th>
<th>mRss 1</th>
<th>mRss 2</th>
<th>FVC 1 ± SD</th>
<th>FVC 2 ± SD</th>
<th>Δ FVC%</th>
<th>Δ DLCO%</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>3.2±1.9</td>
<td>1.6±1.3</td>
<td>1.1±0.9</td>
<td>7.2±5.6</td>
<td>76±20.3*</td>
<td>82.7±22.5*</td>
<td>5.7</td>
<td>1.3</td>
</tr>
<tr>
<td>B</td>
<td>3.1±1.7</td>
<td>1.2±0.9</td>
<td>11.5±3.9</td>
<td>5.6±4.2</td>
<td>77.8±19.7*</td>
<td>86.8±19.7*</td>
<td>8.3</td>
<td>2.1</td>
</tr>
</tbody>
</table>

Notes: in Parameters column 1 = before treatment, 2 = after treatment; M ± SD = mean value and standard deviation; * = significant difference between the values measured before and after the treatment

Conclusion: RTM administration both in combination with IS and as a single-agent therapy in the patients with SSc associated with ILD effectively alleviated skin induration and EScSG, improved or stabilized the pulmonary function parameters. The absence of statistically significant difference in the time course of evaluated parameters between the groups substantiate potential RTM use as a single-agent therapy that, this is most important for the patients with poor tolerability or contraindications to IS administration.

Disclosure of Interests: None declared

on November 4, 2023 by guest. Protected by copyright.